- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Interleukin 32.
Displaying page 1 of 1.
EudraCT Number: 2008-006528-67 | Sponsor Protocol Number: H-A-2008-030 | Start Date*: 2009-03-25 | |||||||||||
Sponsor Name:Hvidovre Hospital, Anæstesiologisk afdeling 532 | |||||||||||||
Full Title: Den perioperative effekt af methylprednisolon ved hoftealloplastik: et prospektivt, dobbeltblindet, placebokontrolleret studie. | |||||||||||||
Medical condition: Total hip arthroplasty, postoperative pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001490-95 | Sponsor Protocol Number: ESPRIT 002: STALWART | Start Date*: 2006-04-21 |
Sponsor Name:National Institute of Allergy and Infectious Diseases (NIAID) | ||
Full Title: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002625-20 | Sponsor Protocol Number: SC052021 | Start Date*: 2021-08-31 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: Intrathecal morphine administration for minimally invasive pancreatic surgery: A double blind, prospective randomized placebo-controlled trial. | ||
Medical condition: postoperative pain treatment after minimally invasive pancreatic surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005154-57 | Sponsor Protocol Number: CACZ885D2307E1 | Start Date*: 2012-01-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndrom... | |||||||||||||
Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) ES (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003561-16 | Sponsor Protocol Number: TAK-242/01-04-TL-242-011 | Start Date*: 2005-12-21 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis | |||||||||||||
Medical condition: Severe sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FI (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003614-13 | Sponsor Protocol Number: hzVSF_v13-0006 | Start Date*: 2020-12-18 | |||||||||||
Sponsor Name:ImmuneMed Inc. | |||||||||||||
Full Title: Efficacy and safety of intravenously administered hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-control... | |||||||||||||
Medical condition: Moderate-to-severe COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001254-22 | Sponsor Protocol Number: SARPAC | Start Date*: 2020-03-24 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients wit... | |||||||||||||
Medical condition: Acute hypoxic respiratory failure of COVID-19 patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001500-41 | Sponsor Protocol Number: COV-AID | Start Date*: 2020-04-03 |
Sponsor Name:University Hospital Ghent | ||
Full Title: A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard ... | ||
Medical condition: COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001540-56 | Sponsor Protocol Number: 208657 | Start Date*: 2019-08-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and cha... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) HU (Completed) ES (Ongoing) NL (Completed) DK (Completed) BE (Completed) DE (Completed) SE (Completed) IE (Completed) IT (Completed) GR (Completed) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001103-31 | Sponsor Protocol Number: AIT02-2001/DMID14-005 | Start Date*: 2015-07-10 | |||||||||||
Sponsor Name:Autoimmune Technologies, LLC | |||||||||||||
Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects wh... | |||||||||||||
Medical condition: Influenza A infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002452-40 | Sponsor Protocol Number: Td500056 | Start Date*: 2023-03-08 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur | ||||||||||||||||||||||||||||
Full Title: Immune Response to Pertussis after Vaccination with a Tdap-IPV Booster Vaccine in Children in the Republic of South Africa: Effect of Homologous and Heterologous Pertussis Vaccination Priming Backg... | ||||||||||||||||||||||||||||
Medical condition: Bacterial infections | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002522-12 | Sponsor Protocol Number: P121001 | Start Date*: 2014-12-10 | |||||||||||
Sponsor Name:Assistance Publique - Hôpitaux de Paris (AP-HP) | |||||||||||||
Full Title: European phase-II clinical trial evaluating efficacy of low dose rhIL-2 in patients with recently diagnosed type 1 diabetes | |||||||||||||
Medical condition: type -I diabetes | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) SE (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002279-16 | Sponsor Protocol Number: EOGBM1-18 | Start Date*: 2020-01-02 | |||||||||||
Sponsor Name:Enterome | |||||||||||||
Full Title: A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIe... | |||||||||||||
Medical condition: Progressive or recurrent Glioblastoma (PG) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016859-22 | Sponsor Protocol Number: CACZ885D2307 | Start Date*: 2013-02-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A one-year open-label, multicenter trial to assess efficacy, safety and tolerability of canakinumab (ACZ885) and the efficacy and safety of childhood vaccinations in patients aged 4 years or younge... | |||||||||||||
Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) GB (Completed) BE (Completed) Outside EU/EEA IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005455-15 | Sponsor Protocol Number: CACZ885D2304 | Start Date*: 2007-06-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A three-part multicenter study, with a randomized, doubleblind, placebo controlled, withdrawal design in Part II to assess efficacy, safety, and tolerability of ACZ885 (antiinterleukin-1β monoclona... | |||||||||||||
Medical condition: Muckle-Wells Syndrome (Autoinflammatory Disease) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000344-21 | Sponsor Protocol Number: MP1032-CT05 | Start Date*: 2021-07-21 | ||||||||||||||||||||||||||
Sponsor Name:MetrioPharm AG | ||||||||||||||||||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PROOF-OF-CONCEPT, PHASE IIA STUDY OF MP1032 PLUS STANDARD OF CARE VS STANDARD OF CARE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH MOD... | ||||||||||||||||||||||||||||
Medical condition: Moderate to severe coronavirus disease 2019 (COVID 19) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed) RO (Ongoing) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003543-11 | Sponsor Protocol Number: 16-214-02 | Start Date*: 2017-07-10 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Ad... | |||||||||||||
Medical condition: Locally Advanced or Metastatic Solid Tumor Malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018077-31 | Sponsor Protocol Number: 012010 | Start Date*: 2010-11-25 |
Sponsor Name:St. Anna Kinderkrebsforschung/CCRI | ||
Full Title: A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA | ||
Medical condition: High-risk neuroblastoma patients having received at least one previous high dose treatment followed by stem cell rescue after conventional therapy fulfilling one of the following criteria: • Prima... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) ES (Ongoing) DE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA) IE (Completed) PL (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002980-26 | Sponsor Protocol Number: CACZ885A2102 | Start Date*: 2004-12-10 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An open-label, phase II dose titration study of ACZ885 (human anti-IL-1beta monoclonal antibody) to assess the clinical efficacy, safety, pharmacokinetics and pharmacodynamics in patients with NALP... | ||
Medical condition: Muckle-Wells Syndrome: rare hereditary, autosomal dominant, systemic inflammatory disease, characterized by recurrent episodes of fever, arthralgia, myalgia, urticarial rash, and conjunctivitis. La... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) ES (Completed) FR (Completed) Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-003612-28 | Sponsor Protocol Number: 206785 | Start Date*: 2021-06-24 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 52-week, randomised, double-blind, double-dummy, parallel group,multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and ad... | |||||||||||||
Medical condition: Severe asthma with an eosinophilic phenotype | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) SI (Trial now transitioned) NO (Trial now transitioned) PL (Completed) FI (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
